Predict your next investment

INDUSTRIAL | Basic Materials / Specialty Chemicals
nucelis.com

See what CB Insights has to offer

Stage

Loan | Acquired

Total Raised

$250K

About Nucelis

Nucelis is a bio-technology company built on a platform of unique, patented technology for optimizing cell structure and function. Nucelis' vision is to change the way industry develops bio-based chemicals by utilizing nature's own production factories such as plants, yeast, and bacteria. Nucelis starts with naturally-efficient organisms that already make a target chemical, and, by enhancing those natural processes, increases that organism's production. Nucelis strives to use sustainable and recyclable feed stocks as starting materials resulting in a process that is less costly and more efficient.

Nucelis Headquarter Location

6465 Nancy Ridge Drive

San Diego, California, 92121,

United States

858-200-1140

Latest Nucelis News

Cibus Subsidiary Nucelis Granted Patent for Increasing Efficiency of Vitamin D Production

May 5, 2020

New Patent Strengthens Cibus’ Comprehensive Intellectual Property Portfolio May 05, 2020 08:00 AM Eastern Daylight Time SAN DIEGO--( BUSINESS WIRE )--Cibus, a pioneer of precision gene editing in agriculture, today announced its microbial strain development subsidiary, Nucelis, has been granted a new patent by the United States Patent and Trademark Office for increasing vitamin D production. In building on both Nucelis’ and Cibus’ comprehensive intellectual property portfolios, the new patent is related to improving vitamin D2 and D3 production — highly valued components in the food, nutraceutical, and pharmaceutical industries. “The new patent further strengthens Nucelis’ position in offering significant improvements in the efficiency and cost to producers of vitamin D2 and D3. This builds on our prior work to make key vitamin D intermediates via fermentation using new yeast strains developed using our proprietary gene-editing technologies,” said Sean O’Connor, Ph.D., President and Chief Executive Officer of Nucelis. “This adds to Cibus’ significant IP portfolio of more than 350 patents that include IP to precisely target natural gene-editing processes in plants and micro-organisms.” “We are excited to publish and protect this new method as efficient and sustainable production of vitamin D is important today as we further understand the importance of vitamin D for human health,” commented Laszlo Treiber, Ph.D., Nucelis Research Fellow and sole inventor on the patent. “The medical community has increased its attention to the importance of vitamin D in the past decade. Vitamin D deficiency has been linked to an increased incidence of bone fractures, cardiovascular disease, autoimmune and thyroid disorders, cognitive degeneration, and certain cancers.” About Cibus Cibus is a biotechnology company using precision gene editing to lead the development of new traits for the global agricultural seed industry. Its family of technologies, known as the Rapid Trait Development System, RTDS™, is broadly applicable to all organisms, including plants, yeast, bacteria, and algae. RTDS edits genes precisely without integrating foreign genetic material to speed development of products genetically indistinguishable from those found in nature. New traits are designed to help agriculture provide more sustainable food sources, reduce agriculture’s impact on the environment, and reduce the impact of climate change. Cibus has established crop platforms in canola, rice, flax, and potato, and is developing platforms in wheat, corn, soybean, and peanut. New traits provide access to multiple royalties through a well-established business model in the multi-billion-dollar global seed market. The company has subsidiaries in Europe and North America and a state-of-the-art research and development center in San Diego, California. About Nucelis Nucelis is a wholly owned subsidiary of Cibus, a biotechnology company with advanced technologies to precisely target and direct a plant’s natural gene-editing processes. The Nucelis Accelerated Strain Advancement Platform (ASAP™) is a specialty ingredient development platform that combines the precision of the Cibus suite of gene-editing technologies, the Rapid Trait Development System (RTDS™), with advanced fermentation and pilot scale facilities and experience, and proprietary downstream, and purification processes. This approach enables Nucelis to efficiently develop and deliver high-value, performance-focused, non-transgenic specialty ingredients for partners in the nutrition, personal care, flavor, and fragrance markets, and for future applications in Ag biologicals, active pharmaceutical ingredients (API’s), human health, and animal health.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Nucelis Patents

Nucelis has filed 8 patents.

The 3 most popular patent topics include:

  • Alkanes
  • Amines
  • Chemical reactions
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/1/2019

4/27/2021

Amines, Ketones, Alkanes, Commodity chemicals, Chemical reactions

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

7/1/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

4/27/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Amines, Ketones, Alkanes, Commodity chemicals, Chemical reactions

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.